Ezetimibe/simvastatin combination not found to increase cancer risk, mortality

Share this content:

the ONA take:

According to a new study published in the American Journal of Cardiology, researchers have found that treatment with ezetimibe/simvastatin (Vytorin) is not linked with an elevated risk for developing cancer or an increased risk of cancer-related mortality.

Researchers identified 1,359 eligible patients for follow-up from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study so that they could investigate new incidences of cancer and total mortality over 21 months following the end of the SEAS trial. Of the 1,359 patients, 1,194 had no history of cancer cancer.

In that portion of patients, 12 patients who received ezetimibe/simvastatin had developed cancer and 22 patients that received placebo developed cancer in the 21-month follow-up (HR 0.55, 95% CI 0.27 - 1.11). During the same period, 43 patients who received ezetimibe/simvastatin and 33 who received placebo died (HR 1.29, 95% CI 0.82 - 2.03).

Results suggest that treatment with the lipid-lowering combination was not linked with an increased risk for developing cancer or dying from cancer during the 21-month follow-up to the SEAS trial. Numerous authors reported financial disclosures with Merck & Co., the manufacturer of Vytorin.

Drug allocation during a shortage
Ezetimibe/simvastatin (Vytorin) is not linked with an elevated risk for developing cancer.
Treatment with the lipid-lowering therapy ezetimibe/simvastatin is not associated with an increased risk of developing cancer or an increased risk of dying from cancer, according to research published in the Nov. 15 issue of the American Journal of Cardiology.
READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs